Krufton (Nilotinib Hydrochloride Dihydrate)

Nilotinib selectively binds to the ATP‑binding pocket of the BCR‑ABL fusion protein, inhibiting its tyrosine‑kinase activity. This blocks downstream signaling pathways that drive uncontrolled proliferation of leukemic cells, thereby reducing disease activity and allowing normal blood cell production.

The specific dose of Krufton is determined by the prescribing physician based on the patient’s clinical condition, disease phase, and individual tolerance. Dosage adjustments may be required according to response and safety monitoring.

Nilotinib is classified as contraindicated in pregnancy and breastfeeding unless the potential benefit justifies the risk. Women of childbearing potential should use effective contraception, and nursing mothers should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Krufton (nilotinib) is a second‑generation tyrosine‑kinase inhibitor offering higher potency against BCR‑ABL than first‑generation agents like imatinib. It is often chosen for patients who need a deeper molecular response or who have developed resistance to earlier therapies, while maintaining an oral dosing schedule.

Krufton tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect the product from moisture, direct sunlight, and excessive heat to maintain stability and potency.

Krufton is taken orally, usually with a low‑fat meal to improve absorption. The tablets should be swallowed whole with water and not crushed or chewed. Patients should follow the dosing schedule prescribed by their clinician.

The most serious risks include QT interval prolongation leading to potential cardiac arrhythmias, severe liver injury, pancreatitis, and significant reductions in blood cell counts such as neutropenia or thrombocytopenia. Regular monitoring of cardiac, hepatic, and hematologic parameters is essential.

Krufton should be avoided in patients with a known hypersensitivity to nilotinib or any component of the formulation, those with uncontrolled cardiac arrhythmias or prolonged QT interval, and individuals taking strong CYP3A4 inhibitors or other QT‑prolonging drugs without appropriate medical supervision.